文献速递骨软组织肉瘤与黑色素瘤

尼达尼布对比异环磷酰胺二线治疗晚期软组织肉瘤的随机II期研究

Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG "ANITA".
PubMed 文献 · Eur J Cancer · 2021-05-29

EORTC-1506-STBSG是一项前瞻性随机开放标签II期试验,比较尼达尼布与异环磷酰胺在晚期不可手术转移性软组织肉瘤一线化疗失败后的疗效与安全性。主要终点为无进展生存期。因中期分析显示尼达尼布组12周无进展患者仅13/36(36%),试验因无效提前终止。尼达尼布组中位PFS 2.5个月,异环磷酰胺组4.4个月(调整HR=1.56,p=0.070)。

要点

  • 尼达尼布二线治疗晚期软组织肉瘤的活性不足,试验因无效提前终止。
  • 尼达尼布组中位PFS 2.5个月,劣于异环磷酰胺组的4.4个月。
  • 尼达尼布常见不良事件为腹泻、疲乏和恶心。

核心结论

  • 试验因无效提前终止,尼达尼布在非选择晚期软组织肉瘤中的活性不值得进一步探索。

研究设计与样本

  • 前瞻性、多中心、随机、开放标签II期试验,比较尼达尼布与异环磷酰胺二线治疗晚期不可手术转移性软组织肉瘤。
  • 患者按1:1随机接受尼达尼布200mg每日两次口服直至疾病进展,或异环磷酰胺3g/m2静脉滴注第1-3天每21天一次最多6周期。
  • 主要终点为无进展生存期,采用Korn设计,目标检测中位PFS从3个月提高到4.5个月(HR=0.667)。
  • 计划中期分析,若前36例尼达尼布治疗患者中12周无进展者少于19例则因无效停止。
  • 共80例患者随机分组,每组40例。

主要发现

  • 中期分析时,前36例可评估的尼达尼布组患者中仅13例(36%)在12周时无进展。
  • 尼达尼布组中位PFS为2.5个月(95%CI:1.5-3.4),异环磷酰胺组为4.4个月(95%CI:2.9-6.7),调整HR=1.56(80%CI:1.14-2.13),p=0.070。
  • 尼达尼布组中位总生存期为13.7个月(95%CI:9.4-23.4),异环磷酰胺组为24.1个月(95%CI:10.9-NE),调整HR=1.65(95%CI:0.89-3.06),p=0.111。
  • 尼达尼布组临床获益率为50%,异环磷酰胺组为62.5%(p=0.368)。
  • 尼达尼布常见治疗相关不良事件(所有级别)为腹泻(35.9%)、疲乏(25.6%)和恶心(20.5%);异环磷酰胺组为疲乏(52.6%)、恶心(44.7%),呕吐、厌食和脱发各占28.9%。

临床怎么用

  • 不推荐尼达尼布用于非选择晚期软组织肉瘤的二线治疗。
  • 异环磷酰胺仍是晚期软组织肉瘤二线治疗的可选药物。

局限性

  • 试验因无效提前终止,样本量有限(共80例)。
  • 研究人群为未选择的软组织肉瘤亚型,结果不一定适用于特定亚型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS). The primary end-point was progression-free survival. PATIENTS/METHODS: Patients with a variety of STS subtypes were randomised 1:1 to nintedanib (200 mg b.i.d. p.o. until disease progression) or ifosfamide (3 g/m2 i.v. days 1-3, every 21 days for ≤6 cycles). A Korn design was applied aiming to detect an improvement in median progression-free survival (mPFS) from 3 to 4.5 months (HR = 0.667). An interim look was incorporated to stop the trial for futility if <19 of the first 36 patients treated with nintedanib were progression-free at week 12. RESULTS: At the interim analysis, among the first 36 eligible and evaluable patients randomised for nintedanib, only 13 (36%) were progression-free at week 12. The trial was closed for further accrual as per protocol. In total, 80 patients were randomised (40 per treatment group). The mPFS was 2.5 months (95% CI: 1.5-3.4) for nintedanib and 4.4 months (95% CI: 2.9-6.7) on ifosfamide (adjusted HR = 1.56 [80% CI: 1.14-2.13], p = 0.070). The median overall survival was 13.7 months (95% CI: 9.4-23.4) on nintedanib and 24.1 months (95% CI: 10.9-NE) on ifosfamide (adjusted HR = 1.65 [95%CI:0.89-3.06], p = 0.111). The clinical benefit rate for nintedanib and ifosfamide was 50% versus 62.5% (p = 0.368), respectively. Common treatment-related adverse events (all grades) were diarrhoea (35.9% of patients), fatigue (25.6%) and nausea (20.5%) for nintedanib; and fatigue (52.6%), nausea (44.7%) and vomiting, anorexia and alopecia (28.9% each) for ifosfamide. CONCLUSION: The trial was stopped for futility. The activity of nintedanib did not warrant further exploration in non-selected, advanced STSs.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schöffski P, Toulmonde M, Estival A, et al. Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG "ANITA". Eur J Cancer. 2021. PMID: 34062484. doi:10.1016/j.ejca.2021.04.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。